Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a mechanistic in vitro study of a engineered nanoparticle system demonstrating proof-of-concept for dual cell death pathways; it lacks clinical outcome data, in vivo efficacy evidence, or comparison to standard therapy.
This is a methodological paper proposing and demonstrating a new evaluation framework for LLMs in safety-critical domains, not a clinical trial or empirical validation of a therapeutic or diagnostic intervention; it raises questions about LLM safety assessment rather than answering clinical questions.